Italy’s Olon expands through Indian plant
Executive Summary
Italian active pharmaceutical ingredient (API) supplier and contract development and manufacturing organisation (CDMO) Olon has expanded its global footprint by striking a deal to buy an API facility in Mahad, India, from Novartis. Describing the plant as “established and reputable”, Olon noted that it “provides a number of lifesaving medicines to the Indian healthcare system and patients around the world”.
You may also be interested in...
Olon CEO Says European Systems Must Value Security Of Supply
With Olon investing significantly in its production capacity and technical capabilities, CEO Paolo Tubertini believes the API specialist is well-positioned to provide resilience within the European supply chain. However, the chief executive also told Generics Bulletin that this robustness needs to be valued by pricing mechanisms.
Olon Expands On Multiple Fronts
Italian API and CDMO specialist Olon is expanding its high-potency capabilities at a site in India, at the same time as unveiling plans to invest a further €30m in a domestic biotech hub.
UAE’s Bioventure Is Looking For Partners To Expand
Having recently added to its biosimilars alliance with Alvotech, Dubai-based Bioventure says it is looking to expand its international reach through further partnerships.